Browse complete Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas Report
Browse all Business Insights Market Research Reports
The flurry of recent industry acquisitions and alliances focused on product portfolios and distribution networks in the Emerging Markets underscores the attractiveness of these areas for the Pharmaceutical industry. This report outlines many of these recent industry alliances, by companies including Pfizer, GSK, Novartis, Abbott, Daiichi Sankyo and others. Many of these alliances have been focused on obtaining the Pharmaceuticals, Generics, Vaccines, OTC’s, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners.
This report provides market forecasts for the major Emerging markets, by IMS and by key industry players. It also outlines the opportunities and challenges presented by market, the major companies focusing on growth in these markets, and the sales and marketing strategies being implemented by specific industry leaders.
Key features of this report
- Coverage of numerous information sources for a comprehensive and up-to-date overview of the subject.
- Evaluation of the opportunities and challenges presented by the 7 major emerging markets as well as Other Asia-Pacific, Latin America, Central and Eastern Europe and Middle East and Africa markets.
- Coverage of market profiles by country and region, including market and epidemiological data
- Coverage of emerging market growth goals, strategies and alliance activity by leading companies
- Extensive analysis of recent government plans for healthcare reform and expanded access in China
Scope of this report
- Identify key Emerging Markets with growth potential for Pharmaceuticals, Generics, vaccines, OTC’s, Hepatitis and HIV/AIDS agents, Biosimilars and 3rd World Vaccines and medicines.
- Learn why China is the key growth opportunity for most companies and the expected pharmaceutical industry impact of the current government plans to expand healthcare insurance and access.
- Understand the unmet medical needs and growth drivers for the major Emerging markets.
- Understand the rationale behind numerous recent industry acquisitions and alliances targeting these markets.
- Identify pharmaceutical and generic companies seeking alliances related to these markets.
- Learn 10 key recommendations for success in these markets, based on experience of industry leaders to date.
Key Market Issues
- Pharmaceutical, biotech and generic companies are targeting the Emerging markets for growth due to declining R+D productivity, significant pending patent expirations and increasing healthcare cost containment measures in the developed markets.
- Opportunities for patented, premium-priced pharmaceuticals, Generics, Biosimilars, Vaccines, OTC’s, Hepatitis and HIV/AIDS agents vary by market.
- The Emerging market opportunities include large population sizes, unmet medical needs, growing economies and increasing public and private healthcare expenditures.
- The challenges encountered in these markets are also numerous and include diverse languages and cultures, healthcare regulations, distribution challenges, preferential treatment for domestic companies and healthcare cost containment measures.
Key findings from this report
- The vast opportunities for Pharmaceuticals in China appear more attainable than ever given the government’s funding of major Healthcare Reforms to increase healthcare access, infrastructure and services between 2009 and 2011. These healthcare reforms aimed at expanding medical insurance and access while decreasing costs are expected to increase pharmaceutical volume at reduced prices.
- India, with its population of 1.1 billion, high levels of poverty and unmet medical needs and low healthcare expenditures continues to present challenges for the global industry. Opportunities include manufacturing skills including Biosimilar manufacturing. However, the lack of Intellectual Property recognition for several biologics, that prompted Novartis’s shift of R+D investment from India to China, is a concern for the innovative industry.
- The large market shares of generics in the Emerging markets have resulted in numerous generic supply deals by companies including Pfizer, GSK, Sanofi Aventis, Novartis, Daiichi Sankyo and Abbott. Other companies that are seeking generic portfolios through alliances or acquisitions include Astra Zeneca, Lilly, J&J and Merck.
- Mylan and Teva appear to be potential alliance partners for companies seeking generics, based on their product portfolios and limited Emerging Market presence.
Key questions answered
- What are the pharmaceutical market sizes, growth forecasts and unmet medical needs in the Emerging markets?
- Is there one definitive list of Emerging markets for Pharmaceuticals?
- What are the opportunities and challenges presented by the major Emerging Market countries and regions?
- How can companies evaluate which Emerging markets offer the greatest opportunities for their growth?
- What are the expectations for the industry impact of the Chinese government’s comprehensive plan for Healthcare reform and expansion?
- Which companies are current industry leaders in terms of Emerging market sales?
About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
